Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Viking TherapeuticsAkebia TherapeuticsSpectrum PharmaceuticalsAffimedCrinetics Pharmaceuticals
SymbolNASDAQ:VKTXNASDAQ:AKBANASDAQ:SPPINASDAQ:AFMDNASDAQ:CRNX
Price Information
Current Price$5.99$2.97$3.01$10.05$17.18
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.81.51.61.8
Analysis Score3.63.33.43.53.4
Community Score3.52.72.82.92.2
Dividend Score0.00.00.00.00.0
Ownership Score0.81.70.80.83.3
Earnings & Valuation Score0.01.30.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$16.44$9.63$9.75$13.80$35.00
% Upside from Price Target174.53% upside224.07% upside224.46% upside37.38% upside103.73% upside
Trade Information
Market Cap$462.30 million$455.90 million$461.95 million$987.29 million$567.44 million
Beta2.022.112.512.811.24
Average Volume1,347,7056,110,7282,578,5863,290,440143,135
Sales & Book Value
Annual RevenueN/A$335 million$109.33 million$23.96 million$1.19 million
Price / SalesN/A1.364.2341.21476.84
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.83 per share$3.32 per share$1.69 per share$0.57 per share$4.84 per share
Price / BookN/A0.891.7817.623.55
Profitability
Net Income$-25,780,000.00$-279,660,000.00$-112,690,000.00$-36,250,000.00$-50,420,000.00
EPS($0.36)($1.63)($1.14)($0.56)($2.09)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-126.86%N/A-172.01%N/A
Return on Equity (ROE)-13.57%-68.51%-98.90%-99.24%-43.35%
Return on Assets (ROA)-13.14%-34.01%-69.77%-37.40%-39.73%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.24%0.05%N/AN/A
Current Ratio27.08%2.15%3.48%2.24%21.98%
Quick Ratio27.09%1.67%3.48%2.24%21.98%
Ownership Information
Institutional Ownership Percentage54.13%68.98%63.56%52.33%92.15%
Insider Ownership Percentage3.70%2.55%5.04%N/A7.10%
Miscellaneous
Employees1837917513793
Shares Outstanding77.18 million153.50 million153.73 million98.29 million33.03 million
Next Earnings Date4/29/2021 (Estimated)5/4/2021 (Estimated)5/6/2021 (Estimated)6/22/2021 (Estimated)5/14/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Crinetics Pharmaceuticals Stock Is Showing Strong Insider InterestCrinetics Pharmaceuticals Stock Is Showing Strong Insider Interest
finance.yahoo.com - April 21 at 1:34 PM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.55Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.55
americanbankingnews.com - April 21 at 12:54 PM
Analyzing Alkermes (NASDAQ:ALKS) and Crinetics Pharmaceuticals (NASDAQ:CRNX)Analyzing Alkermes (NASDAQ:ALKS) and Crinetics Pharmaceuticals (NASDAQ:CRNX)
americanbankingnews.com - April 17 at 2:40 PM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 5.8%Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 5.8%
americanbankingnews.com - April 15 at 2:44 PM
Crinetics Pharmaceuticals (NASDAQ:CRNX)  Shares Down 8.1% Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 8.1%
americanbankingnews.com - April 13 at 2:00 PM
What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
finance.yahoo.com - April 12 at 8:50 AM
Insider Buys Crinetics Pharmaceuticals SharesInsider Buys Crinetics Pharmaceuticals Shares
benzinga.com - April 9 at 1:25 PM
Insider Buying: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Major Shareholder Buys 304,136 Shares of StockInsider Buying: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Major Shareholder Buys 304,136 Shares of Stock
americanbankingnews.com - April 9 at 10:32 AM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.44Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.44
americanbankingnews.com - April 8 at 10:44 AM
 Brokerages Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Will Announce Earnings of -$0.64 Per Share Brokerages Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Will Announce Earnings of -$0.64 Per Share
americanbankingnews.com - April 5 at 2:12 PM
Piper Sandler Weighs in on Crinetics Pharmaceuticals, Inc.s Q2 2021 Earnings (NASDAQ:CRNX)Piper Sandler Weighs in on Crinetics Pharmaceuticals, Inc.'s Q2 2021 Earnings (NASDAQ:CRNX)
americanbankingnews.com - April 2 at 8:50 AM
FY2021 EPS Estimates for Crinetics Pharmaceuticals, Inc. Cut by Cantor Fitzgerald (NASDAQ:CRNX)FY2021 EPS Estimates for Crinetics Pharmaceuticals, Inc. Cut by Cantor Fitzgerald (NASDAQ:CRNX)
americanbankingnews.com - April 2 at 8:50 AM
Brokers Offer Predictions for Crinetics Pharmaceuticals, Inc.s Q1 2021 Earnings (NASDAQ:CRNX)Brokers Offer Predictions for Crinetics Pharmaceuticals, Inc.'s Q1 2021 Earnings (NASDAQ:CRNX)
americanbankingnews.com - April 2 at 8:00 AM
Brokers Set Expectations for Crinetics Pharmaceuticals, Inc.s Q1 2022 Earnings (NASDAQ:CRNX)Brokers Set Expectations for Crinetics Pharmaceuticals, Inc.'s Q1 2022 Earnings (NASDAQ:CRNX)
americanbankingnews.com - April 1 at 9:54 AM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Reaffirmed by SVB LeerinkCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Reaffirmed by SVB Leerink
americanbankingnews.com - April 1 at 8:16 AM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts  Earnings Results, Misses Expectations By $0.08 EPSCrinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Misses Expectations By $0.08 EPS
americanbankingnews.com - March 31 at 7:28 AM
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full ...Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full ...
apnews.com - March 31 at 4:37 AM
Crinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationCrinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 31 at 12:35 AM
Crinetics Pharmaceuticals, Inc. to Host Earnings CallCrinetics Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 30 at 6:32 PM
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial ResultsCrinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 30 at 6:32 PM
Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans ...Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans ...
apnews.com - March 24 at 7:43 AM
Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial ResultsCrinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results
benzinga.com - March 24 at 7:35 AM
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on ...Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on ...
apnews.com - March 12 at 4:56 PM
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical ProgramsCrinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
finance.yahoo.com - March 12 at 4:56 PM
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushings Disease (CRN04894) Advances into Phase 1 StudyCrinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing's Disease (CRN04894) Advances into Phase 1 Study
benzinga.com - February 5 at 6:35 PM
DateCompanyBrokerageAction
1/22/2021Viking TherapeuticsStifel NicolausReiterated Rating
10/29/2020Viking TherapeuticsRaymond JamesBoost Price Target
9/11/2020Viking TherapeuticsWilliam BlairReiterated Rating
9/10/2020Viking TherapeuticsB. RileyReiterated Rating
9/1/2020Viking TherapeuticsBTIG ResearchBoost Price Target
8/31/2020Viking TherapeuticsChardan CapitalBoost Price Target
8/28/2020Viking TherapeuticsHC WainwrightBoost Price Target
7/29/2020Viking TherapeuticsOppenheimerReiterated Rating
6/4/2020Viking TherapeuticsBMO Capital MarketsInitiated Coverage
5/2/2020Viking TherapeuticsMaxim GroupInitiated Coverage
1/2/2020Viking TherapeuticsSVB LeerinkReiterated Rating
3/15/2021Akebia TherapeuticsCantor FitzgeraldInitiated Coverage
1/29/2021Akebia TherapeuticsJPMorgan Chase & Co.Downgrade
9/4/2020Akebia TherapeuticsMorgan StanleyLower Price Target
9/4/2020Akebia TherapeuticsMizuhoLower Price Target
8/11/2020Akebia TherapeuticsNeedham & Company LLCInitiated Coverage
5/6/2020Akebia TherapeuticsRoyal Bank of CanadaBoost Price Target
9/17/2020Spectrum PharmaceuticalsJMP SecuritiesInitiated Coverage
12/26/2019Spectrum PharmaceuticalsGuggenheimDowngrade
3/15/2019Spectrum PharmaceuticalsJefferies Financial GroupReiterated Rating
3/30/2021AffimedCredit Suisse GroupInitiated Coverage
3/30/2021AffimedWells Fargo & CompanyBoost Price Target
8/9/2020AffimedLaidlawReiterated Rating
10/11/2018AffimedSunTrust BanksLower Price Target
12/23/2019Crinetics PharmaceuticalsRoth CapitalInitiated Coverage
8/13/2018Crinetics PharmaceuticalsPiper Jaffray CompaniesInitiated Coverage
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.